Thus, the augmented GD3 in CTCL lesions is considered to, at least, partially suppress IL-17A production from the benign CD4 T cells, possibly via siglec-7, which is dominantly expressed in CD103 fraction. The gene discussed is IL17A; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.